Carmot Therapeutics Begins U.S. IPO Rollout [Seeking Alpha]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Seeking Alpha
The firm's lead candidate, CT-388, has shown statistically significant weight loss in Phase 1/2 trials, at least from initial data. The global market for obesity treatment is projected to reach $51 billion by 2032. I'll provide an update when we learn more about the Carmot Therapeutics IPO. Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More » A Quick Take On Carmot Therapeutics Carmot Therapeutics Inc. CRMO ) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement The firm is a clinical-stage biopharma developing treatments for serious metabolic diseases. Carmot Therapeutics Inc. is well capitalized and has produced intriguing initial efficacy results for its lead candidate. I'll provide an update when we learn more about the IPO from management. Carmot Overview Berkeley, California-based Carmot Therapeutics was founded to develop glucagon-like peptide [GLP]- based trea
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]Seeking Alpha
- Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.MarketBeat
- Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewswire
- Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
LYEL
Sec Filings
- 12/18/25 - Form 424B5
- 12/16/25 - Form EFFECT
- 12/8/25 - Form 8-K
- LYEL's page on the SEC website